Results 191 to 200 of about 77,493 (312)

A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata. [PDF]

open access: yesJ Health Econ Outcomes Res
Cha-Silva AS   +6 more
europepmc   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri   +11 more
wiley   +1 more source

Alopecia areata during dupilumab therapy: 2 cases and review of the literature. [PDF]

open access: yesJAAD Case Rep
Almulhim AN   +5 more
europepmc   +1 more source

Consensus‐based Guideline on tinea capitis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The consensus‐based guideline developed under the auspices of the German Dermatological Society (DDG) is intended to provide physicians with a structured framework for clinical decision‐making in the management of patients with tinea capitis and to contribute to improved diagnostic accuracy, treatment adherence, and prevention. Tinea capitis is
Peter Mayser   +19 more
wiley   +1 more source

PD‐L1‐Inhibitor‐Associated Hidradenitis Suppurativa

open access: yes
Journal of Cutaneous Pathology, EarlyView.
Annie Jin   +2 more
wiley   +1 more source

Ectopic Adipocytes in Scarring Alopecias: Comparison With Normal Scalp and Potential Therapeutic Implications

open access: yes
Journal of Cutaneous Pathology, EarlyView.
Annelise de Almeida Verdolin   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy